Research / ZS / Fundamental state Inspectable configuration
State dimensions Filing 0001713683-21-000175 General Corporate
Debt relative to revenue RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.debt_to_revenue
135.72% · OPTIONAL · NOT_ENOUGH_HISTORY
Capex intensity 42th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.capex_revenue_ratio
7.16% · OPTIONAL · VALID
Operating cash generation 83th Own-history percentile · N=12
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
30.02% · OPTIONAL · VALID
Revenue growth 67th Own-history percentile · N=9
Evidence method Yoy · gp.fundamentals.revenue
56.07% · CORE · VALID
Gross margin 0th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.gross_margin
77.67% · CORE · VALID
Operating margin 8th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.operating_margin
-30.87% · CORE · VALID
R&D intensity 92th Own-history percentile · N=13
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
25.95% · OPTIONAL · VALID
SBC intensity 85th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
38.41% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 34 states Self-history eligible
Oct 31, 2021 7/8 normalized Level 3 Jan 31, 2022 5/6 normalized Level 3 Apr 30, 2022 7/8 normalized Level 3 Jul 31, 2022 8/8 normalized Level 3 Oct 31, 2022 8/8 normalized Level 3 Jan 31, 2023 8/8 normalized Level 3 Apr 30, 2023 8/8 normalized Level 3 Jul 31, 2023 8/8 normalized Level 3 Oct 31, 2023 8/8 normalized Level 3 Jan 31, 2024 6/6 normalized Level 3 Apr 30, 2024 8/8 normalized Level 3 Jul 31, 2024 8/8 normalized Level 3 Oct 31, 2024 8/8 normalized Level 3 Jan 31, 2025 8/8 normalized Level 3 Apr 30, 2025 8/8 normalized Level 3 Jul 31, 2025 7/7 normalized Level 3 Oct 31, 2025 7/7 normalized Level 3 Jan 31, 2026 7/7 normalized Level 3 Apr 30, 2026 7/7 normalized Level 3 Jul 31, 2026 7/7 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 510.34%
Current 135.72%
Delta -374.62% Capex Intensity Decreased
Previous 8.40%
Current 7.16%
Delta -1.24% Cash Generation Decreased
Previous 41.59%
Current 30.02%
Delta -11.57% Growth Decreased
Previous 59.61%
Current 56.07%
Delta -3.53% Margin Decreased
Previous 77.90%
Current 77.67%
Delta -0.24% Profitability Decreased
Previous -24.86%
Current -30.87%
Delta -6.02% R And D Intensity Increased
Previous 23.21%
Current 25.95%
Delta 2.73% Sbc Intensity Increased
Previous 34.00%
Current 38.41%
Delta 4.41% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.